Brief: Medicenna Therapeutics Announces Positive Results On Drug Distribution From Phase 2B Clinical Trial Of MDNA55
21/11/2019 13:20
Nov 21 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA THERAPEUTICS - NEW POSITIVE RESULTS ON DRUG
DISTRIBUTION FROM PHASE 2B CLINICAL TRIAL OF MDNA55 FOR
TREATMENT OF RECURRENT GLIOBLASTOMA
* MEDICENNA THERAPEUTICS CORP - MDNA55-05 STUDY SHOWED
NEARLY 50%
COVERAGE OF TUMOR, WITH SOME PATIENTS ACHIEVING OVER 90%
COVERAGE OF TARGET VOLUME
Source text for Eikon: ID:nPn139BZa
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results